• Mashup Score: 0

    Moderator Jack Cronenwett, MD, asks a group of expert panelists about improving EVAR follow-up across patient populations, advantages and limitations of registry data to evaluate devices, efforts to link data across registries, and how to support future…

    Tweet Tweets with this article
    • Dr. Jack Cronenwett talks w/Drs. @BenjaminSBrooke, Philip Goodney, @KevinMani7, Marc Schermerhorn, @RamonVarcoeMD, & Grace J. Wang on the advantages & limitations of registry data for analysis of long-term #EVAR trends. https://t.co/RVoxG231qV

  • Mashup Score: 0

    Representatives from FDA discuss how “long term” is defined, the goals of and insights from recent panel discussions, use of real-world registries to explore long-term durability, how follow-up can be achieved in the face of real-world challenges, and…

    Tweet Tweets with this article
    • Representatives from FDA, Ronald Fairman, MD, & Carmen Gacchina Johnson, PhD discuss long-term #EVAR outcomes from a regulatory perspective highlighting the impact of recent research & expert panel discussions, obtaining appropriate follow-up data, & more. https://t.co/GUEVuXu1rr

  • Mashup Score: 1

    News and information on minimally invasive vascular disease therapies, covering peripheral vascular disease, aneurysms, stroke, hypertension, dialysis access, and venous issues.

    Tweet Tweets with this article
    • Guest Chief Medical Editors, Drs. Adam Beck (@AWBeckMD) & Anders Wanhainen (@AWanhainen) introduce our feature issue focused on optimizing long-term #EVAR & ensuring essential follow-up. Issue Contents: https://t.co/rUK4PJwhKc https://t.co/c3u69qWrDq